Loading video...

Video Failed to Load

Go Home

🚨Update from #ESMO24 Upper GI cancer data 🚨 Dr Lizzy Smyth & Dr Sam Klempner joined us at ESMO to share their insights into new #UpperGI cancer data & the potential impact on clinical practice. 📺 Watch their video update Supported by Bayer #MedEd #oncology #OncTwitter

giconnectInfo's profile picture

GI CONNECT powered by COR2ED

2,278 subscribers

160,747 views • 2 years ago •via X (Twitter)

#ESMO24#UpperGI#MedEd#oncology#OncTwitter
LIVE

Anya Rossi• Live Now

Private livecam show

1 Comments

Pearse Keane's profile picture
Pearse Keane2 years ago

@LizzySmyth1 @KlempnerSam Great to see this pop up in my feed @LizzySmyth1 😀

Related Videos

Breast Cancer highlights from ASCO 2026! Dr Paolo Tarantino joined us at ASCO to share his expert insights on key trial data from ASCENT-03, ASCENT-04, TROPION-Breast02, SERENA-6, VIKTORIA-1, & OPTIMA How will these data impact clinical practice? 📺 Watch his update to find out! >> Programme endorsed by ICAN, International Cancer Advocacy Network This educational programme is supported by COR2ED
3:06

Breast Cancer highlights from ASCO 2026! Dr Paolo Tarantino joined us at ASCO to share his expert insights on key trial data from ASCENT-03, ASCENT-04, TROPION-Breast02, SERENA-6, VIKTORIA-1, & OPTIMA How will these data impact clinical practice? 📺 Watch his update to find out! >> Programme endorsed by ICAN, International Cancer Advocacy Network This educational programme is supported by COR2ED

COR2ED

2,492,255 views • 3 months ago

Update from ESMO 2025! >> Endometrial & ovarian cancer highlights 📺 Prof. Nicoletta Colombo reviews the latest data in gynecological cancers presented at the congress Could these developments impact clinical practice? Watch to find out! Endorsed by ICAN, International Cancer Advocacy Network This independent programme is supported by COR2ED
5:30

Update from ESMO 2025! >> Endometrial & ovarian cancer highlights 📺 Prof. Nicoletta Colombo reviews the latest data in gynecological cancers presented at the congress Could these developments impact clinical practice? Watch to find out! Endorsed by ICAN, International Cancer Advocacy Network This independent programme is supported by COR2ED

COR2ED

114,711 views • 11 months ago

Catch up on 𝘏𝘌𝘙2-mutant non-small cell lung cancer (NSCLC) data presented at ASCO 2026 Dr Herbert Loong, MBBS, FASCO & Dr Isabel Preeshagul joined us at ASCO 2026 to share their views on data emerging from the meeting 📺 Watch the video to get their expert insights on data from SOHO-01, Beamion LUNG-3, PRO results from the Beamion LUNG-1 trial, and advances in HER2 testing Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer
4:40

Catch up on 𝘏𝘌𝘙2-mutant non-small cell lung cancer (NSCLC) data presented at ASCO 2026 Dr Herbert Loong, MBBS, FASCO & Dr Isabel Preeshagul joined us at ASCO 2026 to share their views on data emerging from the meeting 📺 Watch the video to get their expert insights on data from SOHO-01, Beamion LUNG-3, PRO results from the Beamion LUNG-1 trial, and advances in HER2 testing Programme endorsed by ICAN, International Cancer Advocacy Network, Biomarker Collaborative , Exon 20 Group, a multistakeholder organization & International Society of Liquid Biopsy Supported by an Independent Educational Grant from Bayer

LUNG CONNECT powered by COR2ED

841,885 views • 1 month ago

Just released! Bladder cancer update from ESMO 25 📺 Prof. Thomas Powles shares his bladder cancer highlights & reviews the latest data from KEYNOTE-905, ALBAN & Imvigor011. This independent programme is supported by COR2ED
4:24

Just released! Bladder cancer update from ESMO 25 📺 Prof. Thomas Powles shares his bladder cancer highlights & reviews the latest data from KEYNOTE-905, ALBAN & Imvigor011. This independent programme is supported by COR2ED

COR2ED

229,737 views • 11 months ago

🚨 #LowerGIcancer highlights from #ASCO24 🚨 Prof. Jenny Seligmann & Dr Dominik Paul Modest share their views on new data from #COLLISION & #TRANSMET trials presented at the congress. ⬇️🎥⬇️ #MedEd #ASCOhighlights #CRCSM #LowerGI
2:19

🚨 #LowerGIcancer highlights from #ASCO24 🚨 Prof. Jenny Seligmann & Dr Dominik Paul Modest share their views on new data from #COLLISION & #TRANSMET trials presented at the congress. ⬇️🎥⬇️ #MedEd #ASCOhighlights #CRCSM #LowerGI

GI CONNECT powered by COR2ED

539,590 views • 2 years ago

Today, IMA Senior Fellow, Oncology Dr. Angus Dalgleish testified at Senator Ron Johnson's hearing, 'Plausible Mechanisms of COVID-19 Injections Causing Cancer and Attacks on Scientific Publications. Last week, Dr. Dalgleish joined us to discuss his concerns about the exponential rise in cancer cases and issued a call to action for clinicians and researchers working with cancer patients to speak up and share their observations before this trend worsens. Watch now.
5:55

Today, IMA Senior Fellow, Oncology Dr. Angus Dalgleish testified at Senator Ron Johnson's hearing, 'Plausible Mechanisms of COVID-19 Injections Causing Cancer and Attacks on Scientific Publications. Last week, Dr. Dalgleish joined us to discuss his concerns about the exponential rise in cancer cases and issued a call to action for clinicians and researchers working with cancer patients to speak up and share their observations before this trend worsens. Watch now.

Independent Medical Alliance

24,462 views • 3 months ago

📹 Discover the latest clinical practice changing insights from the ENETS 2026 conference in Krakow, Poland. Prof. Louis de Mestier, Prof. Timon Vandamme, and Dr Alice Durand share insights into new data on PRRT in treatment sequencing and re-challenge in NETs, obrixtamig as 1st line therapy in advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss interesting combination treatment. How will new data impact clinical practice? Watch to find out. This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
5:56

📹 Discover the latest clinical practice changing insights from the ENETS 2026 conference in Krakow, Poland. Prof. Louis de Mestier, Prof. Timon Vandamme, and Dr Alice Durand share insights into new data on PRRT in treatment sequencing and re-challenge in NETs, obrixtamig as 1st line therapy in advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss interesting combination treatment. How will new data impact clinical practice? Watch to find out. This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.

NET CONNECT powered by COR2ED

1,109,836 views • 5 months ago

A stunning clinical observation has set a new course in the fight against cancer. Renowned cancer surgeon Dr. Kathleen Ruddy reveals a medical anomaly that challenges everything we know. After 30 years in oncology, having never witnessed a single case of spontaneous remission, Dr. Ruddy saw three patients experience dramatic responses that could only be attributed to one thing: the repurposed drug Ivermectin. The statistical likelihood of this happening by chance? "It's not zero, but it approaches zero." Faced with this incredible signal, the conventional path—a funded clinical trial—was a dead end. "What do you think the likelihood of that is? That's zero. That's flat-out zero." So, what's the next step? Dr. Ruddy found inspiration in one of medicine's most legendary studies: Framingham. Just as the Framingham Heart Study followed a population over decades without intervention, simply collecting data to make landmark discoveries, Dr. Ruddy is launching a groundbreaking initiative. This will be a Framingham-type observational study for cancer patients. The subjects? Patients who, exercising their right to choose, have already decided to use repurposed, FDA-approved drugs like Ivermectin under their physician's guidance. The central question is powerful in its simplicity: Do drugs like Ivermectin improve survival for cancer patients? This is a pivotal moment for data-driven medicine. It’s a direct response to real-world evidence and a refusal to ignore potential breakthroughs hiding in plain sight. If the signal is confirmed, it could revolutionize oncology. This isn't just observation; it's a mission to follow the data, wherever it leads.
3:06

A stunning clinical observation has set a new course in the fight against cancer. Renowned cancer surgeon Dr. Kathleen Ruddy reveals a medical anomaly that challenges everything we know. After 30 years in oncology, having never witnessed a single case of spontaneous remission, Dr. Ruddy saw three patients experience dramatic responses that could only be attributed to one thing: the repurposed drug Ivermectin. The statistical likelihood of this happening by chance? "It's not zero, but it approaches zero." Faced with this incredible signal, the conventional path—a funded clinical trial—was a dead end. "What do you think the likelihood of that is? That's zero. That's flat-out zero." So, what's the next step? Dr. Ruddy found inspiration in one of medicine's most legendary studies: Framingham. Just as the Framingham Heart Study followed a population over decades without intervention, simply collecting data to make landmark discoveries, Dr. Ruddy is launching a groundbreaking initiative. This will be a Framingham-type observational study for cancer patients. The subjects? Patients who, exercising their right to choose, have already decided to use repurposed, FDA-approved drugs like Ivermectin under their physician's guidance. The central question is powerful in its simplicity: Do drugs like Ivermectin improve survival for cancer patients? This is a pivotal moment for data-driven medicine. It’s a direct response to real-world evidence and a refusal to ignore potential breakthroughs hiding in plain sight. If the signal is confirmed, it could revolutionize oncology. This isn't just observation; it's a mission to follow the data, wherever it leads.

Camus

135,549 views • 1 year ago

🚨 SHOCKING FDA EXPOSÉ: Under Biden, American cancer patients' CELLS were shipped to CHINA for gene-editing—then injected BACK into US bodies WITHOUT proper consent! Dr. Marty Makary just blew the lid off this national security NIGHTMARE. Key FACTS that’ll make your blood boil (2024-2025 data): • 2M+ Americans diagnosed with cancer in 2024—over 5,500 new cases DAILY—yet their DNA was sent to a hostile nation! (Source: American Cancer Society / CDC) • China conducted 11+ human CRISPR trials by 2018, gene-editing cells from 86+ Americans—while the U.S. handed over our genetic data! (Source: Nature, MIT Technology Review) • Biden’s Dec 2024 FDA exemption allowed this—Trump-Vance FDA halted all new trials in June 2025 to protect American DNA! (Source: official announcement) How deep does this betrayal go?
1:12

🚨 SHOCKING FDA EXPOSÉ: Under Biden, American cancer patients' CELLS were shipped to CHINA for gene-editing—then injected BACK into US bodies WITHOUT proper consent! Dr. Marty Makary just blew the lid off this national security NIGHTMARE. Key FACTS that’ll make your blood boil (2024-2025 data): • 2M+ Americans diagnosed with cancer in 2024—over 5,500 new cases DAILY—yet their DNA was sent to a hostile nation! (Source: American Cancer Society / CDC) • China conducted 11+ human CRISPR trials by 2018, gene-editing cells from 86+ Americans—while the U.S. handed over our genetic data! (Source: Nature, MIT Technology Review) • Biden’s Dec 2024 FDA exemption allowed this—Trump-Vance FDA halted all new trials in June 2025 to protect American DNA! (Source: official announcement) How deep does this betrayal go?

Valerie Anne Smith

201,604 views • 9 months ago

🚨 SHOCKING DISCOVERY THEY BURIED: Hydroxychloroquine doesn’t just fight viruses — it turns viruses into precision-guided cancer killers. It allows viruses to attack cancer cells while leaving healthy cells completely untouched. This comes straight from Dr. Richard Urso (ophthalmologist and member of America’s Frontline Doctors) in a powerful presentation. Why was this information suppressed and the data obscured? Because a cheap, decades-old drug that could selectively destroy cancer would be catastrophic for the multi-trillion-dollar cancer industry. They don’t want you to know this. They want you dependent on expensive treatments forever. The truth is out. Share it before it gets buried again.
2:04

🚨 SHOCKING DISCOVERY THEY BURIED: Hydroxychloroquine doesn’t just fight viruses — it turns viruses into precision-guided cancer killers. It allows viruses to attack cancer cells while leaving healthy cells completely untouched. This comes straight from Dr. Richard Urso (ophthalmologist and member of America’s Frontline Doctors) in a powerful presentation. Why was this information suppressed and the data obscured? Because a cheap, decades-old drug that could selectively destroy cancer would be catastrophic for the multi-trillion-dollar cancer industry. They don’t want you to know this. They want you dependent on expensive treatments forever. The truth is out. Share it before it gets buried again.

Dr. Dawn Michael

747,315 views • 3 months ago

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we've engaged in discussions with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medtwitter
0:49

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we've engaged in discussions with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medtwitter

David Fajgenbaum, MD

55,805 views • 1 year ago

Training robot foundation models faces two key hurdles: how to get enough data to train an effective model, and how to make sure that new skills can be acquired quickly. The team at Rhoda AI believes that the answer is training Direct Video Action models from web data. Web data is plentiful, to the point where Rhoda can train their base model on hundreds of years of video data. And then, with the addition of robot data, they can quickly adapt it to new tasks with as little as 20 hours of in-domain data, performing complex, multi-step manipulation tasks with their purpose-built video foundation model. Tongzhou Mu 🤖🦾🦿 Eric Chan and Changan Chen joined us to talk more about their approach. Watch Episode #79 of RoboPapers, with Michael Cho - Rbt/Acc, Chris Paxton, and Jiafei Duan, to learn more!
1:09:10

Training robot foundation models faces two key hurdles: how to get enough data to train an effective model, and how to make sure that new skills can be acquired quickly. The team at Rhoda AI believes that the answer is training Direct Video Action models from web data. Web data is plentiful, to the point where Rhoda can train their base model on hundreds of years of video data. And then, with the addition of robot data, they can quickly adapt it to new tasks with as little as 20 hours of in-domain data, performing complex, multi-step manipulation tasks with their purpose-built video foundation model. Tongzhou Mu 🤖🦾🦿 Eric Chan and Changan Chen joined us to talk more about their approach. Watch Episode #79 of RoboPapers, with Michael Cho - Rbt/Acc, Chris Paxton, and Jiafei Duan, to learn more!

RoboPapers

24,677 views • 4 months ago

🚨 Dr. James Lyons-Weiler just sounded the alarm: A new Michigan bill would FORCE schools to post kids’ vaccination data publicly. “Imagine having a bill that will compel schools, K-12, to disseminate immunization data to [the] Michigan Department of HHS.” “That families could be notified by email that their child’s vaccination status is different from those of their peers.” “This is a form of coercion that puts the family at risk of stigma and harassment.” “Schools having to post the data on websites and display physical notices? Come on.” “This … can lead to conflict between the child … and the parents who may have very good reasons.” James Lyons-Weiler
0:59

🚨 Dr. James Lyons-Weiler just sounded the alarm: A new Michigan bill would FORCE schools to post kids’ vaccination data publicly. “Imagine having a bill that will compel schools, K-12, to disseminate immunization data to [the] Michigan Department of HHS.” “That families could be notified by email that their child’s vaccination status is different from those of their peers.” “This is a form of coercion that puts the family at risk of stigma and harassment.” “Schools having to post the data on websites and display physical notices? Come on.” “This … can lead to conflict between the child … and the parents who may have very good reasons.” James Lyons-Weiler

Children’s Health Defense

17,124 views • 8 months ago

Introducing the Future of AI-Powered Sports Data with $FXI.⚡️ We’re not just talking about innovation, we’re building it. 🚀 From #AI-driven data capture to on-chain validation and data monetization, the FX1 ecosystem is rewriting the rules of the sports and data economy. Our platform empowers leagues, teams, and creators to unlock the full potential of their data with cutting-edge AI solutions. 🧠 Why FX1? ➡️ AI-Powered Precision: Transform raw sports data into actionable insights. ➡️ Data Validation on Chain: Building trust in the data economy through blockchain. ➡️ AI-Powered Revenue Streams: Use sports data to drive predictive analytics, odds modeling, and other high-value solutions that unlock new ways to monetize. FX1 is leading the charge in AI innovation, creating a seamless bridge between sports, blockchain, and the data economy. This isn’t just evolution - it’s a revolution. 💡 The future of sports is here. And it’s powered by AI. 🤖 Watch the full video and see how we’re turning vision into reality. 👇
0:52

Introducing the Future of AI-Powered Sports Data with $FXI.⚡️ We’re not just talking about innovation, we’re building it. 🚀 From #AI-driven data capture to on-chain validation and data monetization, the FX1 ecosystem is rewriting the rules of the sports and data economy. Our platform empowers leagues, teams, and creators to unlock the full potential of their data with cutting-edge AI solutions. 🧠 Why FX1? ➡️ AI-Powered Precision: Transform raw sports data into actionable insights. ➡️ Data Validation on Chain: Building trust in the data economy through blockchain. ➡️ AI-Powered Revenue Streams: Use sports data to drive predictive analytics, odds modeling, and other high-value solutions that unlock new ways to monetize. FX1 is leading the charge in AI innovation, creating a seamless bridge between sports, blockchain, and the data economy. This isn’t just evolution - it’s a revolution. 💡 The future of sports is here. And it’s powered by AI. 🤖 Watch the full video and see how we’re turning vision into reality. 👇

FX1

23,913 views • 1 year ago